Ensysce Biosciences, Inc.
ENSCNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M | $3.9M |
| Operating income | −$10.2M | −$6.7M | −$10.7M | −$24.2M | −$19.9M | −$1.6M |
| Net income | −$10.2M | −$8.0M | −$10.6M | −$24.2M | −$29.1M | $2.4M |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M | $351,807 |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M | $7.0M |
| Equity | $3.2M | $3.7M | −$322,858 | −$3.7M | −$7.9M | −$6.4M |
| EPS (diluted) | $-3.98 | $-11.45 | $-70.40 | $-139.42 | $-1.48 | $0.00 |
| Shares out. | 1.4M | 7.3M | 15.4M | 29.9M | 6.2M | 23.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −202.1%
- Net margin
- −200.8%
- Return on equity
- −316.6%
- Return on assets
- −136.5%
- Return on capital (ROCE)
- −355.0%
- Liabilities / assets
- 61.3%
- Debt / equity
- 1.42×
- Book value / share
- $2.29
- Revenue growth (YoY)
- −2.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -67.26distress
- Accruals / assets
- −31.8%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 17, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-08PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
- Phase 1Recruitingreadout ~2026-12-22Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Adage Capital Management, L.P.Passive (13G)Aug 12, 2025
- Perceptive Advisors LlcPassive (13G)May 15, 2025
- Ra Capital Management, L.P.Passive (13G)Feb 14, 2025
- Anson Funds Management LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Gower Bob GDirector | Mar 2, 2023 | Buy | 90,287 | $0.49 |
| Gower Bob GDirector | Feb 28, 2023 | Buy | 109,300 | $0.49 |
| Gower Bob GDirector | Dec 9, 2022 | Buy | 357,143 | $1.40 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 814,605 | 1.0 | +1444.9% |
| Apr 30, 2026 | 52,730 | 1.0 | -18.0% |
| Apr 15, 2026 | 64,295 | 1.0 | -67.0% |
| Mar 31, 2026 | 194,924 | 1.0 | +46.7% |
| Mar 13, 2026 | 132,839 | 1.0 | -59.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeMay 22, 2026
- Results of operationsMay 15, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventApr 8, 2026
- Director / officer changeApr 3, 2026
- Results of operationsMar 30, 2026
- Director / officer changeMar 30, 2026
- Amended charter or bylawsMar 23, 2026
- Delisting / listing-standard noticeFeb 27, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.